This is a demo store. No orders will be fulfilled.

Ladiratuzumab vedotin (anti-SLC39A6) - Primary antibody, specific to SLC39A6, >90% (SDS-PAGE&SEC), high purity, Human IgG1, INHIBITOR of Tubulin inhibitor, INHIBITOR of Tubulin inhibitor

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Cynomolgus monkey,Human,Mouse
  • Isotype: Human IgG1
  • Conjugation: MC-VC-PAB-MMAE
In stock
Item Number
Ab183329
Grouped product items
SKU Size
Availability
Price Qty
Ab183329-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$189.90
Ab183329-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$919.90
Ab183329-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,299.90
Ab183329-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$3,679.90

Purity>90% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Conjugated (MC-VC-PAB-MMAE)

Basic Description

Product Name Ladiratuzumab vedotin (anti-SLC39A6) - Primary antibody, specific to SLC39A6, >90% (SDS-PAGE&SEC), high purity, Human IgG1, INHIBITOR of Tubulin inhibitor
Synonyms Estrogen regulated protein LIV 1 6 antibody | Estrogen-regulated protein LIV-1 antibody | LIV 1 antibody | LIV 1 protein, estrogen regulated antibody | S39A6_HUMAN antibody | SLC39A6 antibody | Solute carrier family 39 (metal ion transporter), member 6 an
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥90%(SDS-PAGE&SEC-HPLC), See COA
Host species Human
Specificity SLC39A6
Conjugation MC-VC-PAB-MMAE
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type INHIBITOR
Mechanism of action INHIBITOR of Tubulin inhibitor
Product Description

Ladiratuzumab vedotin (anti-SLC39A6) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin (anti-SLC39A6) has the potential for use in multiple carcinomas.
Purity
>90% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

Isotype Human IgG1
Light Chain Type kappa
SDS-PAGE 146.96 kDa
Purification Method Protein A purified
Purity >90% (SDS-PAGE&SEC)
Shape Liquid
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 1629760-29-7

Associated Targets(Human)

SLC39A6 Tbio Zinc transporter ZIP6 (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling SLC39A6 (red) with Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) at 1.0 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - Flow Cytometry
Flow Cytometry analysis of ZDFH001-human-LIV1 A6-C2203027 cells at 1×105 cell/well can bind Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) with the EC₅₀ of 80.0 ng/mL.

Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - SEC
The purity of Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) is more than 95% verified by HPLC.

Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - ELISA
Immobilized Recombinant Human SLC39A6/LIV-1 Protein (rp176717) at 1.0 μg/mL can bind Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) with the EC₅₀ of 18.4 ng/mL.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.